News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,728 Results
Type
Article (39530)
Company Profile (247)
Press Release (655951)
Section
Business (204092)
Career Advice (2007)
Deals (35412)
Drug Delivery (94)
Drug Development (81004)
Employer Resources (172)
FDA (16149)
Job Trends (14842)
News (345025)
Policy (32495)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (4)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (17)
2024 Biotech Beach Digital (8)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (5)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2546)
Accelerated approval (2)
Adcomms (20)
Allergies (80)
Alliances (49362)
ALS (81)
Alzheimer's disease (1345)
Antibody-drug conjugate (ADC) (107)
Approvals (16150)
Artificial intelligence (225)
Autoimmune disease (13)
Automation (14)
Bankruptcy (360)
Best Places to Work (11636)
BIOSECURE Act (18)
Biosimilars (100)
Biotechnology (175)
Bladder cancer (56)
Brain cancer (24)
Breast cancer (245)
Cancer (1957)
Cardiovascular disease (147)
Career advice (1673)
Career pathing (29)
CAR-T (139)
Cell therapy (392)
Cervical cancer (17)
Clinical research (65644)
Collaboration (757)
Compensation (446)
Complete response letters (18)
COVID-19 (2582)
CRISPR (34)
C-suite (203)
Cystic fibrosis (98)
Data (1896)
Decentralized trials (2)
Denatured (16)
Depression (36)
Diabetes (241)
Diagnostics (6326)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (109)
Drug pricing (95)
Drug shortages (25)
Duchenne muscular dystrophy (84)
Earnings (86119)
Editorial (31)
Employer branding (21)
Employer resources (146)
Events (111568)
Executive appointments (626)
FDA (17234)
Featured Employer (47)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (681)
Gene editing (94)
Generative AI (18)
Gene therapy (270)
GLP-1 (677)
Government (4377)
Grass and pollen (4)
Guidances (48)
Healthcare (18802)
Huntington's disease (22)
IgA nephropathy (21)
Immunology and inflammation (101)
Indications (26)
Infectious disease (2710)
Inflammatory bowel disease (131)
Inflation Reduction Act (8)
Influenza (46)
Intellectual property (83)
Interviews (311)
IPO (16484)
IRA (40)
Job creations (3628)
Job search strategy (1422)
Kidney cancer (9)
Labor market (34)
Layoffs (448)
Leadership (15)
Legal (7899)
Liver cancer (70)
Lung cancer (287)
Lymphoma (129)
Machine learning (2)
Management (58)
Manufacturing (264)
MASH (59)
Medical device (13312)
Medtech (13317)
Mergers & acquisitions (19391)
Metabolic disorders (619)
Multiple sclerosis (67)
NASH (16)
Neurodegenerative disease (75)
Neuropsychiatric disorders (24)
Neuroscience (1805)
NextGen: Class of 2025 (6511)
Non-profit (4476)
Northern California (2384)
Now hiring (37)
Obesity (336)
Opinion (201)
Ovarian cancer (71)
Pain (75)
Pancreatic cancer (76)
Parkinson's disease (130)
Partnered (18)
Patents (199)
Patient recruitment (93)
Peanut (46)
People (57045)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20443)
Phase II (28909)
Phase III (21542)
Pipeline (959)
Podcasts (44)
Policy (107)
Postmarket research (2563)
Preclinical (8648)
Press Release (64)
Prostate cancer (91)
Psychedelics (30)
Radiopharmaceuticals (243)
Rare diseases (350)
Real estate (5900)
Recruiting (65)
Regulatory (22107)
Reports (46)
Research institute (2316)
Resumes & cover letters (349)
Rett syndrome (3)
RNA editing (2)
RSV (37)
Schizophrenia (61)
Series A (120)
Series B (77)
Service/supplier (11)
Sickle cell disease (49)
Southern California (2058)
Special edition (14)
Spinal muscular atrophy (147)
Sponsored (28)
Startups (3571)
State (2)
Stomach cancer (12)
Supply chain (59)
The Weekly (25)
United States (20830)
Vaccines (653)
Venture capitalists (37)
Webinars (12)
Weight loss (224)
Women's health (33)
Worklife (15)
Date
Today (26)
Last 7 days (564)
Last 30 days (2599)
Last 365 days (33488)
2025 (7624)
2024 (35218)
2023 (40076)
2022 (51174)
2021 (55711)
2020 (54083)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (717)
Alabama (49)
Alaska (7)
Arizona (223)
Arkansas (13)
Asia (37682)
Australia (6160)
California (5436)
Canada (1853)
China (465)
Colorado (244)
Connecticut (256)
Delaware (123)
Europe (80789)
Florida (809)
Georgia (190)
Idaho (57)
Illinois (488)
India (23)
Indiana (288)
Iowa (9)
Japan (138)
Kansas (100)
Kentucky (23)
Louisiana (7)
Maine (60)
Maryland (822)
Massachusetts (4085)
Michigan (208)
Minnesota (366)
Mississippi (2)
Missouri (75)
Montana (27)
Nebraska (25)
Nevada (56)
New Hampshire (62)
New Jersey (1545)
New Mexico (28)
New York (1560)
North Carolina (908)
North Dakota (7)
Northern California (2384)
Ohio (190)
Oklahoma (14)
Oregon (33)
Pennsylvania (1237)
Puerto Rico (9)
Rhode Island (26)
South America (1094)
South Carolina (18)
South Dakota (1)
Southern California (2058)
Tennessee (92)
Texas (809)
Utah (163)
Virginia (127)
Washington D.C. (57)
Washington State (506)
West Virginia (3)
Wisconsin (48)
695,728 Results for "ocugen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Ocugen, Inc. Announces FDA Alignment on Phase 2/3 Pivotal Confirmatory Clinical Trial for Modifier Gene Therapy Candidate OCU410ST for Stargardt Disease
February 27, 2025
·
6 min read
Press Releases
Ocugen Provides Business Update with Fourth Quarter and Full Year 2024 Financial Results
March 5, 2025
·
13 min read
Press Releases
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of OCU200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
January 16, 2025
·
5 min read
Press Releases
Ocugen, Inc. Announces Dosing Completion in the Phase 2 ArMaDa Clinical Trial for OCU410—a Multifunctional Modifier Gene Therapy for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
February 12, 2025
·
7 min read
Business
Ocugen, Inc. Appoints Huma Qamar, MD, MPH as Chief Medical Officer
Ocugen, Inc. announced the appointment of Dr. Huma Qamar as Chief Medical Officer.
March 18, 2024
·
3 min read
Press Releases
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
January 27, 2025
·
6 min read
Pharm Country
Ocugen to Present at May 2024 Investor Conferences
Ocugen, Inc. announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-founder, Ocugen, will present at The Citizens JMP Life Sciences Conference taking place at the New York Hilton Midtown from May 13 – 14, 2024.
May 10, 2024
·
3 min read
Pharm Country
Ocugen to Present at BIO International Convention 2024
Ocugen, Inc. today announced that the Company will present at the 2024 BIO International Convention taking place in San Diego, CA from June 3 – 6, 2024.
May 29, 2024
·
4 min read
Press Releases
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
January 13, 2025
·
6 min read
Drug Development
Ocugen, Inc. Announces First Patient Dosed in Phase 3 liMeliGhT Clinical Trial for OCU400—First Gene Therapy in Phase 3 with a Broad Retinitis Pigmentosa Indication
Ocugen, Inc. announced that the first patient has been dosed in its Phase 3 liMeliGhT clinical trial for OCU400—a modifier gene therapy product candidate being developed for retinitis pigmentosa.
June 20, 2024
·
7 min read
1 of 69,573
Next
